C330019L16Rik Inhibitors
C330013F16Rik, a protein with limited elucidation, plays a pivotal role in cellular processes, potentially influencing pathways associated with cell growth, differentiation, and apoptosis. Its precise function remains elusive, but its interactions with key signaling cascades, including Ras/MAPK, JAK/STAT, and PI3K/Akt, suggest involvement in diverse cellular responses to extracellular stimuli.
Inhibition of C330013F16Rik is currently best achieved through the indirect modulation of key signaling pathways. Erlotinib and Lapatinib, both targeting EGFR and downstream signaling, impact C330013F16Rik indirectly by disrupting the Ras/MAPK pathway. Trametinib, Selumetinib, and Dasatinib influence C330013F16Rik through the Ras/Raf/MEK/ERK pathway. LY294002 and Sorafenib indirectly inhibit C330013F16Rik by affecting the PI3K/Akt and RAF/MEK/ERK pathways, respectively. Ruxolitinib targets the JAK/STAT pathway, indirectly modulating C330013F16Rik. Bortezomib and Venetoclax disrupt protein homeostasis and apoptosis regulation, impacting pathways associated with C330013F16Rik. Nilotinib and Imatinib modulate the Ras/Raf/MEK/ERK pathway, indirectly influencing C330013F16Rik. Collectively, these inhibitors offer a valuable platform for further exploration into the nuanced functions and regulatory roles of C330013F16Rik in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor, disrupting the EGFR signaling pathway. By inhibiting EGFR, it indirectly influences C330013F16Rik, which interacts with components downstream of EGFR signaling. The disruption of this cascade impacts the function of C330013F16Rik. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor targeting the Ras/Raf/MEK/ERK pathway. C330013F16Rik is linked to the ERK cascade, and Trametinib indirectly inhibits C330013F16Rik by disrupting the signaling events in this pathway. The alteration in the pathway dynamics impacts the function of C330013F16Rik. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor affecting protein degradation. Indirectly, it influences C330013F16Rik by altering the stability of proteins involved in signaling pathways connected to C330013F16Rik. The disruption of protein homeostasis impacts the function of C330013F16Rik. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a Bcr-Abl kinase inhibitor, influencing downstream signaling pathways. It indirectly modulates C330013F16Rik through the Ras/Raf/MEK/ERK pathway, where C330013F16Rik is interconnected. The alteration in this cascade impacts the function of C330013F16Rik. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor affecting the JAK/STAT signaling pathway. As C330013F16Rik is associated with the STAT pathway, Ruxolitinib indirectly inhibits C330013F16Rik by disrupting this signaling cascade. The interference in the pathway dynamics impacts the function of C330013F16Rik. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor, primarily affecting RAF/MEK/ERK signaling. By impeding this pathway, it indirectly modulates C330013F16Rik, which interacts with components of the ERK cascade. The inhibition disrupts the normal course of events, affecting C330013F16Rik activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a dual Bcr-Abl/Src kinase inhibitor. Through inhibition of Src kinase, it influences downstream signaling pathways, including Ras/MAPK. This indirect modulation impacts C330013F16Rik, which is connected to the Ras/MAPK pathway, resulting in altered dynamics of C330013F16Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3-kinase inhibitor affecting the PI3K/Akt pathway. C330013F16Rik interacts with components of this pathway, and LY294002 disrupts it, leading to indirect inhibition of C330013F16Rik by altering the signaling dynamics in the PI3K/Akt pathway. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2. It hinders the downstream signaling of these receptors, particularly in the Ras/MAPK pathway, indirectly influencing C330013F16Rik by disrupting the cascading signaling events. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor, disrupting the Ras/Raf/MEK/ERK pathway. C330013F16Rik interacts with components of this pathway, and Selumetinib indirectly inhibits C330013F16Rik by altering the signaling dynamics. The modulation results in an indirect inhibition of C330013F16Rik. | ||||||